News: Another NICE boost for Inditherm
AIM-listed Rotherham company, Inditherm, has received further backing from the National Institute for Health & Care Excellence (NICE) for its innovative medical products.
Manvers-based Inditherm has developed products using low voltage carbon polymer technology to provide heat. Its systems are used for patients undergoing operations which carry risk of inadvertent hypothermia and in neonatal wards.
NICE published guidance in 2011 advising that the Inditherm patient warming mattress should be considered for use in patients at risk of inadvertent hypothermia. The NHS in England alone could save over £15m per annum if forced air warming was replaced by Inditherm's mattress for eligible procedures in most of the 3,030 operating theatres.
NICE is recognised as being a world leader in setting standards for high quality healthcare and are the most prolific producer of clinical guidelines in the world. It has recently published adoption support information to try and help NHS hospitals plan and start using Inditherm patient warming.
Under the Health Technologies Adoption Programme, the information is based on consultations with users of the Inditherm system from four different NHS Trusts that have converted from forced air warming as a primary hypothermia prevention technology. Some of the benefits reported from the NHS users and highlighted by NICE were: improved outcomes; cost savings; practical benefits including ease of use and set-up; and environmental benefits.
The case studies show that Inditherm products can help prevent perioperative hypothermia and in turn reduce infection rates, use of blood products, recovery times and mortality. They also show that Trusts can make substantial cost savings whilst maintaining, or in some cases improving, patient care.
Nick Bettles, chief executive at Inditherm, said: "This is a very comprehensive set of documents that should certainly help NHS trusts in their preparations for adoption of Inditherm as their primary perioperative patient warming in place of traditional forced air warming. The amount of information, all based on real life experience in an NHS environment and independently prepared by NICE, should facilitate uptake elsewhere.
"The fact that this has been carried out with direct input from four independent NHS trusts who have all implemented the change, experienced the issues first hand and realised the benefits in practice should give other hospitals confidence to adopt Inditherm patient warming, with all the advantages it clearly delivers."
Earlier this month Inditherm reported a 23% rise in its turnover to £2.1m for the year to 31 December 2013 – up from £1.7m in the previous year. Pre-tax losses fell from £176,000 to £93,000.
Inditherm website
Images: Inditherm
Manvers-based Inditherm has developed products using low voltage carbon polymer technology to provide heat. Its systems are used for patients undergoing operations which carry risk of inadvertent hypothermia and in neonatal wards.
NICE published guidance in 2011 advising that the Inditherm patient warming mattress should be considered for use in patients at risk of inadvertent hypothermia. The NHS in England alone could save over £15m per annum if forced air warming was replaced by Inditherm's mattress for eligible procedures in most of the 3,030 operating theatres.
NICE is recognised as being a world leader in setting standards for high quality healthcare and are the most prolific producer of clinical guidelines in the world. It has recently published adoption support information to try and help NHS hospitals plan and start using Inditherm patient warming.
Under the Health Technologies Adoption Programme, the information is based on consultations with users of the Inditherm system from four different NHS Trusts that have converted from forced air warming as a primary hypothermia prevention technology. Some of the benefits reported from the NHS users and highlighted by NICE were: improved outcomes; cost savings; practical benefits including ease of use and set-up; and environmental benefits.
The case studies show that Inditherm products can help prevent perioperative hypothermia and in turn reduce infection rates, use of blood products, recovery times and mortality. They also show that Trusts can make substantial cost savings whilst maintaining, or in some cases improving, patient care.
Nick Bettles, chief executive at Inditherm, said: "This is a very comprehensive set of documents that should certainly help NHS trusts in their preparations for adoption of Inditherm as their primary perioperative patient warming in place of traditional forced air warming. The amount of information, all based on real life experience in an NHS environment and independently prepared by NICE, should facilitate uptake elsewhere.
"The fact that this has been carried out with direct input from four independent NHS trusts who have all implemented the change, experienced the issues first hand and realised the benefits in practice should give other hospitals confidence to adopt Inditherm patient warming, with all the advantages it clearly delivers."
Earlier this month Inditherm reported a 23% rise in its turnover to £2.1m for the year to 31 December 2013 – up from £1.7m in the previous year. Pre-tax losses fell from £176,000 to £93,000.
Inditherm website
Images: Inditherm
0 comments:
Post a Comment